Our previous studies demonstrated that the promyelocytic leukemia gene, PML which involved in the 15;17 translocation in acute promyelocytic leukemia (APL) is a growth and transformation suppressor. In this study, recombinant PML adenovirus, Ad-PML was constructed and used to infect human breast cancer cells in vitro and in vivo, the anti-oncogenic function of PML and its mechanism of growth suppressing eect in breast cancer cells were examined. We showed that Ad-PML eectively infected the MCF-7 and SK-BR-3 cells. A high level of PML protein was expressed within 24 h postinfection and a detectable level remained at day 16. Ad-PML signi®cantly suppressed the growth rate, clonogenicity, and tumorigenicity of breast cancer cells. Intratumoral injections of MCF-7-induced tumors by high titer Ad-PML suppressed tumor growth in nude mice by about 80%. The injection sites expressed high level of PML and associated with a massive apoptotic cell death. To elucidate the molecular mechanism of PML's growth suppressing function, we examined the eect of Ad-PML on cell cycle distribution in MCF-7 and SK-BR-3 cells. We found that Ad-PML infection caused a cell cycle arrest at the G1 phase. We further showed that G1 arrest of MCF-7 cells is associated with a signi®cant decrease in cyclin D1 and CDK2. An increased expression of p53, p21 and cyclin E was found. The Rb protein became predominantly hypophosphorylated 48 h post-infection. These ®ndings indicate that PML exerts its growth suppressing eects by modulating several key G1 regulatory proteins. Our study provides important insight into the mechanism of tumor suppressing function of PML and suggests a potential application of Ad-PML in human cancer gene therapy.
Introduction
The promyelocytic leukemia (PML) gene was ®rst identi®ed in the nonrandom chromosomal translocation t(15;17)(q22;q12) associated with acute promyelocytic leukemia (APL) (Goddard et al., 1991; de The et al., 1991; Kakizuka et al., 1991; Pandol® et al., 1991; Chang et al., 1992) . The PML's gene product belongs to a novel family of proteins characterized by a C3HC4 RING-®nger, two additional Cys/His-rich motifs, and an a-helical coiled-coil region Borden et al., 1995) . PML protein was found to be the major component of a novel form of nuclear body designated PML oncogenic domain (POD) (Dyck et al., 1994) . In addition to PML, POD was found to contain at least six other cellular proteins such as Sp-100 (Szostecki et al., 1990) , NDP55 (Ben-Chetrit et al., 1988) , a 65-kd protein (Weis et al., 1994) , NDP52 (Korioth et al., 1995) , PIC1 (Boddy et al., 1996) , and Int-6 (Desbois et al., 1996) . The integrity of the POD is disrupted in leukemic blasts from patients with APL and the APLderived NB4 cell line. All trans-retinoic acid (ATRA) or arsenic trioxide treatment of APL cells induced dierentiation and apoptosis which is associated with a reorganization of wild-type POD structure (Dyck et al., 1994; Weis et al., 1994; Chang et al., 1995) . Some viral proteins such as ICPO (Maul et al., 1993) , the adenoviral protein E1A, E4-ORF3, and E1B (Carvalho et al., 1995; Doucas et al., 1996) . Epstein-Barr nuclear protein 5 (Szekely et al., 1996) , and a novel ubiquitin-speci®c protease (Everett et al., 1997) are shown to target and reorganize PODs. These studies demonstrated that after virus infection a dramatic structural change in the PODs was found, suggesting that PODs are the target of tumor virus oncoproteins. Interestingly, during adenovirus infection, Sp-100 and NDP55 but not PML relocated from the POD to a unique nuclear elongated ®brous structures (viral inclusion bodies) (Doucas et al., 1996) , indicating that viral oncoproteins, e.g. E4-ORF, may release PML-associated factors from POD and possibly promote transformation. It was hypothesized that POD may play a role in sequestration of important cellular regulatory proteins.
Studies on the biologic function of PML in our laboratory demonstrated that PML is a growth and transformation suppressor (Mu et al., 1994 (Mu et al., , 1996 Liu et al., 1995) . Our previous study further showed that the nuclear localization domain, the dimerization domain, and RING-®nger motif are necessary for suppressing transformation of NIH3T3 by activated neu oncogene . Recently, we established stable transfectant of PML in HeLa cells and further showed that PML exerts a strong negative growth control over these cells (Mu et al., 1996) . We also extend our studies to other human cancer cell lines and found that overexpression of PML in these cells such as HeLa, PC-3, DU145, LNCaP, SK-OV3 and SW-13 remarkably inhibited their growth in vitro (He et al., 1997; Mu et al., 1997 and our unpublished data) . This growth suppressor function of PML was also reported by other groups which showed that overexpression of PML by transient transfection induced a sharp reduction in growth rates Ahn et al., 1995) . It was reported that when breast and colon cancers turned invasive, the expression of PML was lost . Our study and others demonstrated that the wild-type PML is expressed in all cell lines tested. This suggests that PML may be an essential protein factor for cell growth regulation. Together, the above studies suggests that PML may have a general anti-oncogenic properties and may play an important role in the pathogenesis of a variety of solid tumors.
Breast cancer is one of the major cancer burdens worldwide and is the most common cancer among women in the United States (Forbes, 1997) . The existing hormonal, chemotherapeutic, immunologic, surgery, and radiation treatments have provided a signi®cant improvement for the survival of patients with localized disease, while treatment for metastatic brest cancer remains essentially palliative (Hortobagyi et al., 1996) . The median survival for patients diagnosed with metastatic breast cancer is in the range of 17 ± 20 months, and the 5-year survival rate is only 15% (Piccart, 1996) . Because metastatic breast cancer is an incurable disease, eorts to reduce mortality must focus on early diagnosis and novel improved treatments. During the past 3 years, two of the genes designated BRCA1 and BRCA2, which confer a signi®cant increased susceptibility to breast and ovarian cancers have been isolated and characterized (Miki et al., 1994; Wooster et al., 1995) . Analysis of these genes as well as the tumor-suppressor gene, p53 allow detection of susceptible individuals before a tumor develops. The development of new treatments for breast cancer is an area of intense research. For example, scheduling and dose-intensity, new agents (e.g. paclitaxel and topoisomerase inhibitors), immunologic therapy, and targeting therapy to inhibition of growth factor receptor (e.g. EGFR and Her-2/neu), matrix metalloproteinase, and angiogenesis in breast cancer have been intensively investigated (Hortobagyi et al., 1996) . Gene therapy could be one of the most important therapeutic approaches for treating human breast cancer in the future. In the preclinical experiments, in vivo delivery of p53 (Katayose et al., 1995; Lesoon-Wood et al., 1995; Runnebaum and Kreienberg, 1995) , adenovirus type 5 early region 1A (E1A) , human interleukin-2 or interleukin-1 (Su et al., 1994) , interferon (Zhang et al., 1996) , Bcl-xs (Ealovega et al., 1996) , and suicide gene (Yee et al., 1996; Kwong et al., 1996) have been shown to prevent/delay and suppress breast cancer growth in nude mice.
To examine PML's anti-oncogenic function in breast cancer, its potential in cancer gene therapy, and its molecular mechanisms of growth suppression, wildtype PML was expressed in a replication-de®cient adenovirus-mediated gene delivery system and introduced into human breast cancer cells in vitro and in vivo. Our study demonstrated that Ad-PML significantly suppresses growth and tumorigenicity of breast cancer cells. Intratumoral injection of Ad-PML into tumors induced by MCF-7 cells dramatically suppressed their growth. The molecular mechanism of PML growth suppressing function in breast cancer cells was also examined in this study.
Results

Ad-PML infection eciency and expression of the PML protein in breast cancer cells
Expression of the PML protein was con®rmed by infecting the MCF-7 and SK-BR-3 cells with Ad-PML followed by immuno¯uorescence staining and Western blotting. MCF-7 and SK-BR-3 cells or in cells infected with Ad-ASPML express low level of endogenous PML protein as shown by immuno¯uorescence staining (Figure 1Aa and 1Ac) . After Ad-PML infection (Figure 1Ab and 1Ad) , a dramatic increase in PML expression was found. Ad-ASPML infection neither aect the expression of PML nor their growth rate. We therefore have chosen the Ad-ASPML as a negative control for the subsequent studies.
The unique nuclear speckled staining pattern of PML allows one to easily assess the infection eciency of Ad-PML in the breast cancer cells. As shown in Table 1 , both MCF-7 and SK-BR-3 cells were eectively infected by the Ad-PML. Over 85% eciency can be achieved at a multiplicity of infection (MOI) of 50 and 10 for MCF-7 and SK-BR-3 cells, respectively. Consistent infection eciency was also observed by infecting with recombinant adenovirus, Ad-CMVbGal (Kleinerman et al., 1995) , and staining for b-galactosidase activity (data not shown). This study showed that SK-BR-3 cells are more susceptible to Ad-PML infection than the MCF-7 cells.
High level of PML expression in the breast cancer cells after Ad-PML infection was also con®rmed by Western blotting (Figure 1B ± E). MCF-7 and SK-BR-3 cells were infected with Ad-PML at various MOI and the level of PML expression was determined at various time points by Western blot analysis. The endogenous PML protein expressed in MCF-7 and SK-BR-3 cells was low and undetectable by Western blotting. After infection with Ad-PML, an increased expression of the 90 kDa PML protein was detectable at increasing MOI ( Figure 1D and E). Figure 1B and C showed the time course of PML expression after Ad-PML infection. The expression of PML rapidly increased after 10 h post-infection and reached a maximum level between 24 ± 48 h. A high level of PML was maintained until 10 days post-infection. PML level declined until it reaches a low but detectable level at day 16 ( Figure 1B and C) . These results demonstrated that Ad-PML eectively infects breast cancer cell lines and expresses high level of protein in vivo.
The eect of Ad-PML infection on soft agar clonogenicity of MCF-7 and SK-BR-3 cells Our preliminary study showed that Ad-PML infection of MCF-7 and SK-BR-3 cells signi®cantly inhibited their growth rate (data not shown). To study the eect of Ad-PML on clonogenicity of breast cancer cells on soft agar, Ad-PML and Ad-ASPML infected (using a MOI that achieve an infection eciency of about 85%) SK-BR-3 and MCF-7 cells were spread on soft agar, and their ability to form colonies were investigated. The results as shown in Figure 2 demonstrated that Ad-PML signi®cantly suppressed the colony-forming ability of MCF-7 and SK-BR-3 cells relative to that of the control virus, Ad-ASPML. These experiments were independently repeated at least three times and consistent observation was obtained.
The eect of Ad-PML on tumorigenicity of breast cancer cells in nude mice
To examine the ability of Ad-PML in suppressing tumorigenicity of breast cancer cells, we ®rst infected the MCF-7 cells in vitro with Ad-PML or Ad-ASPML at a MOI of 50 and then injected into the mammary fat pads (mfp) of nude mice to assess their ability to suppress or delay tumor growth in vivo. This study demonstrated that all of the animals injected with the cells preinfected with Ad-ASPML began to develop tumors after day 7 and formed large tumors with a mean tumor volume of about 506 mm 3 at day 48, whereas all of those mice injected with cells preinfected with Ad-PML did not develop tumor at day 48 ( Figure  3 and Table 2 ). However, on day 55, small palpable and slow growing tumors were found in three of ®ve mice treated with Ad-PML ( Table 2 ). The tumor growth rate of Ad-ASPML control group was found to be similar to that of the untreated MCF-7 induced tumors, which was performed in a separate set of experiments prior to this study (data not shown). These results demonstrated that Ad-PML inhibited the tumorigenic potential of MCF-7 cells and signi®cantly delayed tumor formation in vivo. A   0H  2H  4H  6H  D2  D3  D4  D7  D10  D14  D16  D18  10H  20H  0  6  12  25  50  100 
Suppression of MCF-7 induced tumor growth in vivo by intratumoral injection of Ad-PML
To further evaluate the therapeutic potential of Ad-PML on human tumor growth induced by MCF-7 cells in vivo, we investigated the ability of Ad-PML in suppressing tumor growth in vivo by intratumoral injection of high titer recombinant PML adenovirus. Consistent with the above results, mice injected with 5610 6 MCF-7 cells began to develop palpable tumors at mfp on day 7, with an average tumor volume of 5, 77, and 500 mm 3 on days 10, 26, and 44, respectively ( Figure 4 and Table 3 ). As shown in Figure 1C , expression of the PML protein persisted for 16 days post-Ad-PML infection and that adenovirus rarely integrates. It is therefore necessary to repeat the Ad-PML administration over a longer experimental period. In this study we injected 1610 9 pfu (plaque forming units) of Ad-PML or Ad-ASPML in about 16 days interval on days 10, 26, and 44. As shown in Figure 4 , a signi®cant inhibition of tumor growth was found in tumors injected with Ad-PML when compared to the tumors injected with Ad-ASPML control.
To examine whether the intratumoral injected Ad-PML expressed the respective PML protein, immunohistochemical staining of the tumor section after Ad-PML infection was performed. As shown in Figure 5A and B, a dramatic increase in PML expression in the tumor surrounding the injection sites was found. Expression of PML was found to spread over a broad area of the tumor surrounding the sites of injection indicating that the injected Ad-PML diused to the neighboring tumor cells and eectively infected and suppressed their growth. This study demonstrated that Ad-PML suppresses MCF-7 induced tumor growth in vivo.
Intratumoral injection of Ad-PML induced tumor cell death by apoptosis
To investigate whether PML induces tumor cell death by apoptosis, tumor sections were stained with ApopTaq in situ apoptosis detection kit (Oncor) to identify apoptotic cells in vivo. Result as shown in Figure 5C demonstrated an extensive apoptosis occurred within the tumor surrounding the injection sites which expressed high level of PML. This study thus demonstrated that intratumoral injection of Ad-PML suppressed tumor growth and induced massive tumor cell death by apoptosis.
To further con®rm the eect of Ad-PML on apoptosis of MCF-7 cells, the Ad-PML infected cells were stained with Hoechest 33258 to identify chromatin condensation in response to apoptotic cell death. Results as shown in Figure 5E Figure 2 The eect of Ad-PML on clonogenicity of breast cancer cells. The eect of Ad-PML infection of SK-BR-3 and MCF-7 cells on soft agar colony formation was performed as described in Materials and methods. Control panels show the number of colonies formed by the parental cells. Ad-control panels show the number of colonies formed after being infected with Ad-ASPML. The lower panels show the number of colonies formed by SK-BR-3 and MCF-7 cells after Ad-PML infection Figure 3 The eect of Ad-PML pre-infection on tumorigenicity of MCF-7 cells in nude mice. MCF-7 cells were pre-incubated with 50 MOI of Ad-PML and its eects on tumorigenicity after injection into the mammary fat pad (mfp) of female nude mice was performed as described in Materials and methods. In the control group, MCF-7 cells were infected with the Ad-ASPML ASPML ( Figure 5D ). We subsequently isolated the low molecular weight DNA from cells at various time points after Ad-PML infection. Result as shown in Figure 5F demonstrated that a signi®cant level of DNA laddering was detected 84 h post-infection, a typical feature of cell death by apoptosis. These studies demonstrated that Ad-PML infection induced apoptotic cell death in breast cancer cells.
Ad-PML induces G1 cell cycle arrest of MCF-7 and SK-BR-3 cells
The above study demonstrated that Ad-PML induced apoptosis of MCF-7 induced tumor cells in nude mice.
To further examine the molecular mechanism of growth inhibition mediated by Ad-PML, MCF-7 and SK-BR-3 cells were infected with Ad-PML or Ad-ASPML, and cells were harvested at dierent time points. The eect of Ad-PML on the distribution of dierent cell cycle phases were anlaysed by¯ow cytometry as described in Materials and methods. As shown in Figure 6 , Ad-PML infection resulted in a signi®cant increase in the number of cells in G1 and decrease the number of cells in S phase in both MCF-7 and SK-BR-3 cells 60 h post-infection. The number of cells at G1 increased from 45% at 0 h to 61% at 60 h post-infection in MCF-7 cells and from 67% at 0 h to 87% at 60 h post-infection in SK-BR-3 cells, respectively. This observation indicates that overexpression of PML induced G 1 arrest of the breast cancer cells. In contrast, no signi®cant changes in the number of cells in G1 was observed in those cells infected with Ad-ASPML.
The eect of Ad-PML on expression of cell cycle regulatory proteins in MCF-7 cells
To investigate the molecular events assoicated with the cell cycle regulation, Western blot analysis was performed to examine the eect of Ad-PML on the expression of cell cycle regulatory proteins in subcon¯uence cultured cells. We ®rst analysed the expression of cylin D1 which is associated with early G 1 . In this study no eort was made to detect cyclin D2 and D3 because they are not expressed in the MCF-7 cells (Gorospe et al., 1996) . Results as shown in Figure 7 indicated that cyclin D1 protein level decreased signi®cantly after 10 h of Ad-PML but not the Ad-ASPML infection. The expression of CDK2 protein also decreased signi®cantly after 48 h of Ad-PML infection. Cyclin E protein level increased rapidly after 10 h although a gradual increase was found after 24 h infected with Ad-ASPML. We next examined the expression of several cyclin dependent kinase (CDK) inhibitors known to act on G 1 . No signi®cant changes in p27 protein expression were observed in Ad-PML infected cells (data not Figure 4 Suppression of tumor growth in vivo by intratumoral injection with Ad-PML. The eect of Ad-PML on in vivo tumor growth was examined by direct injection with high titer virus at multiple sites as described in Materials and methods. The MCF-7 cells were injected into the mfp of nude mice on day 0 to induce tumor formation. The arrowheads indicate the days the tumors were injected with 1610 9 Ad-PML. The control groups were injected with Ad-ASPML The Ad-PML infected MCF-7 cells (5610 6 ) were injected into two sites of mfp in each mouse as described in Materials and methods. b Signi®cant values (P) between Ad-PML and Ad-ASPML groups at dierent time points were calculated using Student's t-test (P values 50.01). Number in parentheses represents the number of mice used in each group of experiment shown). The expression of p16 was undetectable (data not shown), which is in agreement with the ®nding that this gene is homozygously deleted in MCF-7 cells (Lukas et al., 1995) . We found that the expression of p21 protein was signi®cantly elevated following Ad-PML infection (Figure 8) but not in cells infected with Ad-ASPML. A moderate increase in the expression of p53 protein was also detected suggesting that increased , 1993) . Our study further demonstrated that the unphosphorylated form of the retinoblastoma protein (pRb) increased noticeably at 24 h and the protein became predominantly hypophosphorylated at 48 h post-infection with Ad-PML. Our study presented above strongly support a role of PML in cell cycle progression and apoptosis.
Discussion
Signi®cant progress has been made in the past decade in understanding the molecular mechanism of carcinogenesis and cancer biology. Many improved treatment strategies for breast cancer therapy has been introduced to reduce fatality from this deadly disease. Our study here demonstrated a remarkable suppression of growth and tumorigenicity of breast cancer cells in vitro and in vivo by the recombinant PML adenovirus, Ad-PML. This study indicates that Ad-PML has therapeutic potential in the gene therapy of human breast cancer. There are other reports which explored the feasibility of adenovirus mediated gene transfer in breast cancer gene therapy. For example, recombinant adenovirus of p53 (Katayose et al., 1995; LesoonWood et al., 1995; Runnebaum and Kreienberg, 1995) , inferferon (IFN) (Zhang et al., 1996) , E1A , interleukin-2 (Su et al., 1994) , herpes simplex virus thymidine kinase gene (HSV-tk) (Yee et al., 1996; Kwong et al., 1996) , and Bcl-xs (Ealovega et al., 1996) have been shown to inhibit tumor growth in nude mice. Our studies presented in this report demonstrated that Ad-PML could be a much more superior gene to be used in cancer gene therapy due to the following reasons: (1) Comparatively, PML is a much more stable protein, our results demonstrated that infection of MCF-7, SK-BR-3 ( Figure 1 ) and prostate cancer cell lines (He et al., 1997) with Ad-PML expressed high level of PML protein and a detectable level of PML persisted for up to 16 ± 18 days post-infection. This longer lasting eect of PML may be an advantage over the shorter expression period of some of the tumor suppressor proteins e.g. p53. The stable nature of PML protein (with a half-life of about 6 h, unpublished result) enables a high-level of protein accumulated in a b Figure 6 Ad-PML induced G1 cell cycle arrest in SK-BR-3 and MCF-7 cells. MCF-7 (a) and SK-BR-3 (b) cells were infected with Ad-PML or Ad-ASPML, cells were harvested at each time point indicated and the cell cycle distribution was determined by¯ow cytometry as described in Materials and methods cells and decreased the frequency of adenovirus administration as well as the adverse immunological response. (2) Ad-PML infection directly induces tumor cell death by apoptosis without the need of administration of additional agents, e.g. administration of ganciclovir is required for HSV-tk gene therapy and low dose chemotherapeutic agent is required for Adp53 to achieve a more eective tumor suppressing eect. Our study indicated that breast cancer cells are sensitive to adenoviral infection which is in agreement with the recent report that breast cancer cells consist of a high number of adenovirus receptors (6 ± 9610 3 /cell) (Seth et al., 1996) . Results presented in Figures 3 and 6 suggest that Ad-PML resistant population of MCF-7 cells exist within the culture. To provide further understanding of the molecular mechanism of PML's tumor suppressing function, it would be important to isolate and to characterize these resistant clones. This study is currently under way in our laboratory.
There is evidence indicated that PML gene is the direct target of IFN action (Lavau et al., 1995; Stadler et al., 1995) . Analysis of the 5' genomic DNA sequence of the PML gene revealed the existence of INF-a/-b-stimulated responsive element (ISRE) and IFN-g activation site (GAS) in the untranslated ®rst exon (Stadler et al., 1995) and that the accumulation of PML transcripts induced by a-IFN treatment did not require de novo protein synthesis (Lavau et al., 1995) , indicating that increased expression of PML transcripts is a primary response of IFN action. In cooperation with all-trans retinoic acid, IFN has been shown to potentiate the growth inhibition and survival of APL-derived NB4 cells (NasonBurchenal et al., 1996) . Therefore, we speculate that a combination of Ad-PML and Ad-IFN may exhibit a synergistic eect on the inhibition of breast cancer cell growth and tumorigenicity.
In our previous studies, we hypothesized that inactivation of the PML growth suppressor in combination with the disruption of the retinoid pathways aecting normal cell dierentiation are responsible for the development of the APL phenotype (Mu et al., 1994) . During the past 2 years, two groups have reported the growth suppressor function of PML Ahn et al., 1995) , which is inconsistent with our ®nding (Mu et al., 1994; . Results presented in this study further con®rmed PML's growth suppressing function and extend this function in solid tumor. Expression of the PML protein was found in all cell lines tested although its expression varies markedly between cell types (Dyck et al., 1994; Weis et al., 1994; Chang et al., 1995; and our unpublished result) . This ubiquitous expression pattern of PML in cultured cells suggests that it may be an important protein involved in the regulation of cell proliferation and/or dierentiation.
The growth suppressing function of PML has been extensively studied in our laboratory. However, the molecular mechanism of its growth suppressing eect remains unclear. Our studies presented here demonstrated that expression of PML led to a G1 cell cycle arrest indicating that PML induces a blockade of cell cycle progression from G1 to S. Cell cycle progression in mammalian cells is regulated by coordinated action of CDK in association with speci®c regulatory cyclin proteins. Primary regulators of G1 progression are the D-type cyclins (D1, D2, and D3), cyclin E, their catalytic partners, CDKs 2, 4, and 6, and related CDK inhibitors (including p21WAF1, p27KIP1, and p16) (Sherr, 1994) . We found that PML overexpression signi®cantly reduced the expression of cyclin D1 and CDK2 suggesting that these may be partly responsible for the G1 arrest. Interestingly, we found that a signi®cant increase in the expression of p21/WAF1, a CDK inhibitor, and a moderate increase in p53 expression after Ad-PML infection. This result indicates that overexpression of p21 may be responsible for the decrease in CDK2 phosphorylation. Our Ad-PML Ad-ASPML Figure 8 The eects of Ad-PML on the expression of cell cycle dependent kinase inhibitor and tumor suppressor. Total protein isolated from cells infected with Ad-ASPML was used as a negative control. All ®lters were re-probed with the actin antibody to monitor the quantity of protein loaded on each lane. Lanes 6, 10, 24, and 48 indicate the various time points (in hours) after Ad-PML or Ad-ASPML infection. Lane N indicates total proteins isolated from the parental MCF-7 cells. pRb, retinoblastoma protein; ppRb, the phosphorylated form of pRb ®nding that pRb became predominantly hypophosphorylated 48 h post-Ad-PML infection is not unexpected due to the signi®cant increase in p21 and the decrease in CDK2. The signi®cance of PML induced up-regulation of cyclin E is currently unclear.
Since cyclin E is normally expressed at late G1, this observation together with the ®nding that cyclin D1 level decreased after Ad-PML infection, suggests that PML induced a cell cycle arrest at the late G1 phase. Our study thus demonstrated that PML induces G1 cell cycle arrest by modulating the expression of several key proteins in cell cycle regulation. These ®ndings strengthen our current understanding on the biologic function of PML and its role in regulation of cell cycle progression.
Our results as shown in Figure 5C , D and F demonstrated that PML induced a dramatic apoptotic cell death 84 h after Ad-PML infection. As shown in Figure 6 , PML induced a G1 cell cycle arrest in about 60 h post-Ad-PML infection. These results strongly suggest that overexpression of PML induced a G1 cell cycle arrest and subsequently trigger cell death by apoptosis. We have attempted to establish stable PML clone in several cell lines but without success, we observed a massive cell death (¯oating cells) in cells overexpressed PML. The only cell line we were able to establish a stable clone is HeLa (Mu et al., in press ). We found that overexpression of PML in these cells induced an elongation of the G1 phase of the cell cycle and pRb was predominantly hypophosphorylated. This ®nding is consistent with the results presented in this report that PML plays an important role in modulating cell cycle progression from G1 to S. Furthermore, our recent study demonstrated that PML is a substrate of cyclin A/CDK2 (Mu et al., unpublished result) , and that PML phosphorylation was highest at the S phase and decreased to a minimum at G1. These studies further support a role of PML in cell cycle control. From these studies, we conclude that PML exerts its growth suppressing function by modulating several key cycle regulatory proteins normally control cell cycle progression.
Materials and methods
Cell culture
Cell line 293 (obtained from ATCC) was maintained in minimum essential medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 5% tryptose phosphate broth (GIBCO BRL, Bethesda, ML), and 2 mM glutamine. Human breast cancer cell lines MCF-7 and SK-BR-3 were maintained in DMEM containing 10% fatal bovine serum (FBS), 100 units/ml of penicillin, and 100 mg/ml of streptomycin.
Antibodies
The polyclonal PML antibody was raised against the GST ± PML fusion protein in rabbit. The monoclonal antibodies to p16, p21/WAF1, p27, cyclin D1, and cyclin E were purchased from Oncogene Research Products (Cambridge, MA). The monoclonal antibody to CDK2 and actin were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and Amersham Life Science Inc. (Arlington Heights, Il), respectively. The antibodies to pRb and p53 were obtained from Upstate Biotechnology (Lake Placid, NY).
Construction and production of the recombinant PML adenovirus
The recombinant PML adenovirus, Ad-PML, and the antisense PML adenovirus, Ad-ASPML, were constructed and produced as described in our previous report (He et al., 1997) . The average titers of Ad-PML and Ad-ASPML used in these studies were about 5610 10 and 1610 11 plague forming units (pfu)/ml, respectively.
Immuno¯uorescence staining and determination of viral infectivity in MCF-7 and SK-BR-3 cells MCF-7 and SK-BR-3 cells were seeded on coverslides for 4 h, then Ad-PML at various MOI were added and incubated at 378C for an additonal 24 h. Cells were washed in PBS and ®xed in 4% paraformaldehyde. Immuno¯uorescence staining was performed using the polyclonal antibody raised against GST ± PML fusion protein at a dilution of 1 : 1500. Infection eciency was determined by counting the number of cells expressed high level of PML.
Soft agar clonogenicity assay
The eect of Ad-PML infection on anchorage-independent growth of the breast cancer cell lines was determined by soft agar clonogenicity assays as described in our previous report (Mu et al., 1994) .
Western blot analysis and evaluation of PML expression in Ad-PML infected MCF-7 and SK-BR-3 cells
Western blotting was performed as described in our previous report . To determine the dosage-dependent expression of PML protein, various MOI of Ad-PML were used to infect MCF-7 and SK-BR-3 cells. Cells were harvested 24 h post-infection and total proteins were isolated as described previously . To determine the duration of expression of the PML protein after Ad-PML infection, MCF-7 and SK-BR-3 cells were infected with Ad-PML at MOI of 50 and 10, respectively, and culture medium was replaced every 3 days after infection. At the indicated time points, total proteins were isolated and used for Western blotting.
Eect of Ad-PML on tumorigenicity of MCF-7 cells in nude mice
In this study MCF-7 cells were pre-infected with Ad-PML and its eect on tumorigenicity was examined in nude mice. Brie¯y, MCF-7 cells were infected with Ad-PML at a MOI of 50 pfu/cell. An equal amount of cells were preinfected with Ad-ASPML as a control. Three hours after infection, cells were harvested by trypsinization and washed twice with PBS. For each treatment, 5610 6 cells in 0.1 ml were injected into two mammary fat pads (mfp) of each 4 ± 6-week-old BALB/c athymic nude mice (Harlan Sprague-Dawley, Houston, TX). Five mice per group were used for each treatment. Nude mice experiment was reviewed and approved by institutional animal welfare committees for both animal care and use for recombinant DNA research. All mice were maintained under speci®c pathogen-free conditions at our experimental animal core center and given sterile food and water. A 60-day release pellet containing 0.72 mg of 17b-estradiol (Innovative Research of America, Sarasota, FL) was implanted subcutaneously using a 10-gauge trochar into each animal 24 h before the injection.
The eect of intratumoral injection of Ad-PML into MCF-7 induced tumor
In this study 5610 6 of exponentially growing MCF-7 cells in 0.1 ml of PBS were injected into mfp of each female athymic nude mice. Once the tumors became palpable, intratumoral injection at multiple sites with 1610 9 pfu of Ad-ASPML per tumor were performed in a group of ®ve mice. Tumors from another group of ®ve mice were injected with 1610 9 pfu of Ad-PML at multiple sites. Multiple injections with the same concentration of virus were performed at about a 2 week interval. Tumor sizes were measured once a week by the same observer and the tumor volume in mm 3 was calculated as described previously (Kleinerman et al., 1995) .
Immunohistochemical staining
Tumors induced by MCF-7 cells in nude mice were injected with 1610
9 Ad-PML. After 4 days, tumors were removed and ®xed in 10% formalin solution for 16 h. Formalin®xed and paran-embedded sections were cut into 5 mm sections and mounted on silane-coated slides. The sections were deparanized in xylene, dehydrated in alcohol, and rinsed in distilled water. The sections were then washed in PBS, and heated twice in a microwave oven for 5 min in 0.01 M citrate buer (pH 6.0). Endogenous peroxidase activity was blocked by incubation with 3% H 2 O 2 in methanol for 30 min. Nonspeci®c binding of primary antibodies was blocked by incubation with 5% skim milk for 30 min and sections were then incubated with the PML polyclonal antibody (dilution of 1 : 5000) at room temperature for 2 h. The slides were then washed ®ve times with PBS, incubated for 30 min at room temperature with 1 : 30 diluted biotinylated anti-immunoglobulins link (BioGenex, San Ramon, CA), and followed by incubation in label reagent (BioGenex) for 30 min at RT. After applying the substrate solution (BioGenex), the slides were washed thoroughly with distilled water and mounted with aqueous mounting oil.
In vivo cell death assay
Tumors induced by MCF-7 cells in nude mice were injected with Ad-PML at multiple sites as described above. Tumors were removed and ®xed in formalin, paran-embedded sections were prepared (5 mm/section). The eect of Ad-PML on cell death by apoptosis was determined using the ApopTag in situ apoptosis detection kit (Oncor, Gaithersburg, MD) according to the manufacturer's procedure.
DNA staining with Hoechst 33258
Morphological change in the nuclear chromatin of breast cancer cells undergoing apoptosis were detected by staining with the DNA-binding¯uorochrome bis(benzimide)trihydrochloride (Hoechst 33258). Exponentially growing MCF-7 and SK-BR-3 cells were infected with Ad-PML or Ad-ASPML for 76 h. Cells were trypsinized, washed twice with PBS, cytospined on slides and then ®xed in 4% paraformaldehyde at room temperature for 20 min. After washing with PBS, the cells were incubated with 8 mg/ml of Hoechst 33258 (Sigma) in PBS for 20 min. The slides were then washed with distilled water, mounted in Vectasheild mounting medium (Vetor Laboratories, Inc, Burlingame, CA), and observed under a¯uorescence microscope.
DNA laddering analysis
DNA fragmentation as a result of apoptotic cell death following infection with Ad-PML in MCF-7 and SK-BR-3 cells was performed by a modi®ed method originally described by Wyllie (1980) . Brie¯y, MCF-7 and SK-BR-3 cells infected with Ad-PML or Ad-ASPML at dierent time points were trypsinized, detached cells were spun down, and lysed in buer containing 10 mM Tris, 1 mM EDTA, and 0.2% Triton for 30 min on ice. The lysate was centrifuged at 13 500 g for 10 min. The pellet and the supernatant fractions were resuspended in the above lysis buer and incubated with 200 mg/ml proteinase K for 1 h at 508C and extracted with phenol and chloroform. Then DNA was precipitated overnight at 7208C in one volume of ethanol and 0.13 M NaCl. After treatment with 1 mg/ml DNase free RNase A for 1 h at 508C, the DNA was electrophoresed in 1.8% agarose gel.
Cell cycle analysis
Distribution of various cell cycle phases was analysed bȳ ow cytometer after staining with propidium iodide according to our previous report .
